U.S. Markets open in 3 hrs 41 mins

Sinovac Biotech Ltd. (SVA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.470.00 (0.00%)
At close: 9:44AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.47
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's Range6.47 - 6.47
52 Week Range6.47 - 6.47
VolumeN/A
Avg. Volume0
Market Cap642.437M
Beta (5Y Monthly)0.05
PE Ratio (TTM)6.66
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters

    UPDATE 2-Sinovac in talks about setting up South Africa vaccine production

    China's Sinovac Biotech is in talks about setting up a vaccine production facility in South Africa to supply the African continent with shots against a range of diseases, the chief executive of its local partner said on Friday. Numolux Group CEO Hilton Klein made the comments at the launch of the South African leg of a global Phase III trial of Sinovac's COVID-19 vaccine in children and adolescents.

  • Reuters

    Sinovac in talks about setting up S.Africa vaccine production, partner says

    China's Sinovac Biotech is in talks about setting up a vaccine production facility in South Africa with its local partner, the chief executive of the partner said on Friday. Numolux Group CEO Hilton Klein made the comments at the launch of the South African leg of a global Phase III trial of Sinovac's COVID-19 vaccine in children and adolescents. "This clinical trial is a precursor to the establishment of a South African vaccine manufacturing facility partnered by Sinovac and Numolux Group that will cover the entire spectrum of vaccinations beyond just the COVID-19 response," Klein told a news conference.

  • Reuters

    UPDATE 1-Sinovac to trial COVID-19 vaccine in South African children as part of global study

    China's Sinovac Biotech will trial its COVID-19 vaccine in children and adolescents in South Africa as part of a global Phase III study, Sinovac and local partner Numolux Group said on Thursday. The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years, the firms said in a statement. The global trial will enrol 14,000 participants across Chile, the Philippines, Malaysia and Kenya, including 2,000 in South Africa, they said.